Advanced search
Publication Cover
Biomarkers Volume 22, 2017 - Issue 3-4
Submit an article Journal homepage
199
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Elevated serum YKL-40 levels in patients with Kawasaki disease

K. Y. KimDepartment of Pediatrics, Yonsei University College of Medicine, Severance Children’s Hospital, Seoul, South Korea;
,
Y. AhnDepartment of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea
,
D. Y. KimDepartment of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea
,
Ho-Seong KimDepartment of Pediatrics, Yonsei University College of Medicine, Severance Children’s Hospital, Seoul, South Korea;
&
D. S. KimDepartment of Pediatrics, Yonsei University College of Medicine, Severance Children’s Hospital, Seoul, South Korea; Correspondence[email protected]
Pages 326-330 | Received 20 Apr 2016, Accepted 06 Nov 2016, Published online: 09 Dec 2016

References

  • Ahmed, S.F., et al., 2015. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. Journal of the European academy of dermatology and venereology, 29 (4), 682–688.
  • Erfan, G., et al., 2015. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Molecular and cellular biochemistry, 400 (1–2), 207–212.
  • Hattori, N., et al., 2009. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock, 32 (4), 393–400.
  • Johansen, J.S., 2006. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Danish medical bulletin, 53 (2), 172–209.
  • Johansen, J.S., et al., 2003. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast cancer research and treatment, 80 (1), 15–21.
  • Johansen, J.S., et al., 2000. Serum YKL-40 is increased in patients with hepatic fibrosis. Journal of Hepatology, 32 (6), 911–920.
  • Johansen, J.S., et al., 1999. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford), 38 (7), 618–626.
  • Kastrup, J., 2012. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology, 217 (5), 483–491.
  • Kim, D.S., 2006. Kawasaki disease. Yonsei medical journal, 47 (6), 759–772.
  • Kim, K.Y. and Kim, D.S., 2016. Recent advances in Kawasaki disease. Yonsei medical journal, 57 (1), 15–21.
  • Kjaergaard, A.D., et al., 2015. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke, 46 (2), 329–335.
  • Kocyigit, I., et al., 2015. The serum YKL-40 level is associated with vascular injury and predicts proteinuria in nephrotic syndrome patients. Journal of Atherosclerosis and thrombosis, 22 (3), 257–264.
  • Lee, C.G., et al., 2011. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annual review of physiology, 73, 479–501.
  • Liu, X., et al., 2014. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Medical Oncology, 31 (8), 85.
  • Peltomaa, R., et al., 2001. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatology international, 20 (5), 192–196.
  • Rath, T., et al., 2011. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology, 46 (11), 1369–1380.
  • Rathcke, C.N. and Vestergaard, H., 2009. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovascular diabetology, 8, 61.
  • Wang, H.L., et al., 2013. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients. International Journal of Molecular sciences, 14 (11), 22817–22825.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.